Julie Parsonnet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julie Parsonnet has a total of 374 co-authors. Here are the top co-authors by number of shared publications:
- Shuchi Anand
Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA
9 shared publications - Catherine Ley
Stanford University
8 shared publications - Maria E. Montez- Rath
Division of Nephrology, Department of Medicine, Stanford University, Stanford, California
8 shared publications - Jialin Han
Division of Nephrology, Stanford University School of Medicine, Palo Alto, California
7 shared publications Catherine Ley
Infectious Diseases, Stanford University, School of Medicine , Palo Alto, California , USA
6 shared publicationsGlenn M. Chertow
Department of Medicine (Nephrology), Stanford University, Palo Alto, California
6 shared publications
Latest Publications
- 8 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 394 (6820)
The human gut microbiome primes fever after vaccination
Fever is a common adverse reaction to vaccination, contributing to vaccine hesitancy and reduced uptake. To understand variation in fever risk, we longitudinally profiled fecal microbiota, oral temperature, and serological markers in 171 healthy adults receiving Severe acute respiratory syndrome coronavirus 2 mRNA vaccines. Fever risk correlated with low-grade intestinal inflammation, increased abundance of flagellated Lachnospiraceae bacteria, and increased flagellin expression prevaccine. Microbiomes from fever-high donors triggered stronger inflammation in human intestinal organoids and drove flagellin-dependent vaccine reactions in gnotobiotic mice. Moreover, microbiome flagellin phenotypes and murine vaccine reactions were modifiable by diet. Consistent with this, human fever risk was associated with self-reported diet and metabolic markers. These findings identify the gut microbiome as a driver of vaccine-induced fever, suggesting that microbiome-targeting strategies could modulate immune tone and improve vaccine side effects.
- 8 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 394 (6820)
The human gut microbiome primes fever after vaccination
Fever is a common adverse reaction to vaccination, contributing to vaccine hesitancy and reduced uptake. To understand variation in fever risk, we longitudinally profiled fecal microbiota, oral temperature, and serological markers in 171 healthy adults receiving Severe acute respiratory syndrome coronavirus 2 mRNA vaccines. Fever risk correlated with low-grade intestinal inflammation, increased abundance of flagellated Lachnospiraceae bacteria, and increased flagellin expression prevaccine. Microbiomes from fever-high donors triggered stronger inflammation in human intestinal organoids and drove flagellin-dependent vaccine reactions in gnotobiotic mice. Moreover, microbiome flagellin phenotypes and murine vaccine reactions were modifiable by diet. Consistent with this, human fever risk was associated with self-reported diet and metabolic markers. These findings identify the gut microbiome as a driver of vaccine-induced fever, suggesting that microbiome-targeting strategies could modulate immune tone and improve vaccine side effects.
- 16 June 2026
- Published by Wiley in American Journal of Industrial Medicine
- Vol. 69 (9) , 687-695
Beyond Water, Rest, and Shade: Advancing Farmworker Heat Protection Through Partnership
Heat affects farmworker health and productivity. As occupational heat exposure intensifies, cooling devices that extract body heat could protect farmworkers. Companies already market many such technologies to athletes. However, few studies have evaluated their effectiveness, particularly among farmworkers, for whom field‐feasibility, workflow integration, and cost‐at‐scale are critical. In this commentary, we first describe how heat affects farmworker health and review current heat illness prevention standards. We then highlight how cooling devices can augment existing measures and underscore the critical need to test their effectiveness, adaptability, and cost–benefit among farmworkers. Advancing this work requires addressing valid yet surmountable research barriers and building trusted partnerships among researchers, farmworkers, employers, and policymakers. As heat interrupts an increasing number of workdays over time, effective cooling strategies during outdoor work will prove critical to sustaining our nation's food supply.
- 16 June 2026
- Published by Wiley in American Journal of Industrial Medicine
- Vol. 69 (9) , 687-695
Beyond Water, Rest, and Shade: Advancing Farmworker Heat Protection Through Partnership
Heat affects farmworker health and productivity. As occupational heat exposure intensifies, cooling devices that extract body heat could protect farmworkers. Companies already market many such technologies to athletes. However, few studies have evaluated their effectiveness, particularly among farmworkers, for whom field‐feasibility, workflow integration, and cost‐at‐scale are critical. In this commentary, we first describe how heat affects farmworker health and review current heat illness prevention standards. We then highlight how cooling devices can augment existing measures and underscore the critical need to test their effectiveness, adaptability, and cost–benefit among farmworkers. Advancing this work requires addressing valid yet surmountable research barriers and building trusted partnerships among researchers, farmworkers, employers, and policymakers. As heat interrupts an increasing number of workdays over time, effective cooling strategies during outdoor work will prove critical to sustaining our nation's food supply.
- 29 January 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (6) , 1666-1669
Flush with data: harnessing emergency department wastewater as an innovative approach for surveillance of infectious diseases
Wastewater surveillance was widely adopted during the COVID-19 pandemic, where it proved useful in providing timely, actionable public health information. However, reliance on data from large wastewater treatment plants can be inadequate when rapid, local insights are needed. In this article, we propose integrating routine wastewater surveillance for transmissible infectious diseases within US emergency department settings. Monitoring wastewater from the emergency department is a promising innovation which could allow for more rapid generation of actionable data, deepen our understanding of community-level infectious disease burden, and better inform public health efforts.
- 29 January 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (6) , 1666-1669
Flush with data: harnessing emergency department wastewater as an innovative approach for surveillance of infectious diseases
Wastewater surveillance was widely adopted during the COVID-19 pandemic, where it proved useful in providing timely, actionable public health information. However, reliance on data from large wastewater treatment plants can be inadequate when rapid, local insights are needed. In this article, we propose integrating routine wastewater surveillance for transmissible infectious diseases within US emergency department settings. Monitoring wastewater from the emergency department is a promising innovation which could allow for more rapid generation of actionable data, deepen our understanding of community-level infectious disease burden, and better inform public health efforts.
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (2) , 185-186
Pelayo Correa, MD, FAACR: In Memoriam (1927–2025)
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (2) , 185-186
Pelayo Correa, MD, FAACR: In Memoriam (1927–2025)
- Open Access
- 10 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Use of Intrathecal Amphotericin for Coccidioidal Meningitis
Background: Cases of coccidioidomycosis are increasing dramatically in the U.S. The utility of intrathecal (IT) amphotericin in treating coccidioidal meningitis (CM) in the era of azole therapy is unknown. We sought to understand how IT therapy is associated with mortality. Methods: We conducted a retrospective chart review of adult patients with laboratory-proven CM seen at Stanford Healthcare by an Infectious Diseases physician from 2008-2023. Results: 57 patients met inclusion criteria. All patients received azole therapy. Twenty-seven of those patients (47.4%) additionally received IT amphotericin. Patients receiving IT therapy had had a higher median initial CSF WBC at diagnosis (462.5 vs. 188, p = 0.05), higher rates of IV liposomal amphotericin use (88.9% vs. 56.7%, p = 0.02) and corticosteroid use (51.9% vs. 26.7%, p = 0.09), and higher median therapeutic switches per year (0.84 vs. 0.44, p = 0.01). An unadjusted Kaplan-Meier curve demonstrated a five-year mortality rate of 26.7% in the IT amphotericin group, compared to 6.7% in non-receiver group, p = 0.28. A Cox regression revealed that older age at diagnosis (HR 1.07, 95% CI 1.03-1.11), receipt of IT amphotericin (HR 13.9, 95% CI 1.93-100.48), and corticosteroid use (HR 8.3, 95% CI 1.92-35.4) were significantly associated with mortality, with a significant interaction between IT amphotericin and corticosteroids (interaction HR 0.14, 95% CI 0.02-0.97). Conclusions: Patients who received IT amphotericin had higher mortality rates than those who did not, likely reflecting disease refractory to treatment. More therapies are needed for those who have disease progression on azole therapy.
- 10 November 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (11)
Open AccessUse of Intrathecal Amphotericin for Coccidioidal Meningitis
Background: Cases of coccidioidomycosis are increasing dramatically in the U.S. The utility of intrathecal (IT) amphotericin in treating coccidioidal meningitis (CM) in the era of azole therapy is unknown. We sought to understand how IT therapy is associated with mortality. Methods: We conducted a retrospective chart review of adult patients with laboratory-proven CM seen at Stanford Healthcare by an Infectious Diseases physician from 2008-2023. Results: 57 patients met inclusion criteria. All patients received azole therapy. Twenty-seven of those patients (47.4%) additionally received IT amphotericin. Patients receiving IT therapy had had a higher median initial CSF WBC at diagnosis (462.5 vs. 188, p = 0.05), higher rates of IV liposomal amphotericin use (88.9% vs. 56.7%, p = 0.02) and corticosteroid use (51.9% vs. 26.7%, p = 0.09), and higher median therapeutic switches per year (0.84 vs. 0.44, p = 0.01). An unadjusted Kaplan-Meier curve demonstrated a five-year mortality rate of 26.7% in the IT amphotericin group, compared to 6.7% in non-receiver group, p = 0.28. A Cox regression revealed that older age at diagnosis (HR 1.07, 95% CI 1.03-1.11), receipt of IT amphotericin (HR 13.9, 95% CI 1.93-100.48), and corticosteroid use (HR 8.3, 95% CI 1.92-35.4) were significantly associated with mortality, with a significant interaction between IT amphotericin and corticosteroids (interaction HR 0.14, 95% CI 0.02-0.97). Conclusions: Patients who received IT amphotericin had higher mortality rates than those who did not, likely reflecting disease refractory to treatment. More therapies are needed for those who have disease progression on azole therapy.
- Open Access
- 16 November 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (12) , ofae683
Implementing Oral Antibiotics for Bone and Joint Infections: Lessons Learned and Opportunities for Improvement
Background: Although intravenous antibiotics have historically been the standard of care for bone and joint infections, clinical trial data have highlighted the safety and efficacy of oral antibiotics. Despite this, intravenous antibiotics are still commonly used, and evaluations of institutional guidelines advancing oral antibiotic use are limited. Methods: In April 2023, we implemented a new institutional guideline to preferentially treat patients with bone and joint infections with oral antibiotics. The postguideline cohort was compared with a historical preguideline cohort via retrospective chart review. The primary outcome was the proportion of patients discharged exclusively on oral antibiotics. Secondary outcomes included 90-day treatment failure, length of stay, and adverse effects. Results: One hundred eighty-six patients (53 preguideline and 133 postguideline) were included in the analysis. Patients in the postguideline cohort were more likely to be discharged exclusively on oral antibiotics (25% vs 70%; P < .01), with no difference in 90-day treatment failure (8% vs 9%; P = .75). Patients in the postguideline cohort had a shorter length of stay than preguideline (median, 8 vs 7 days; P = .04) and trended toward fewer peripherally inserted central catheter–related adverse events (6% vs 1%; P = .07). Conclusions: An institutional guideline was effective in increasing the proportion of patients with bone and joint infections discharged on oral antibiotics. We observed similar clinical outcomes after implementing the guidelines while reducing length of hospital stay.
- 16 November 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (12) , ofae683
Open AccessImplementing Oral Antibiotics for Bone and Joint Infections: Lessons Learned and Opportunities for Improvement
Background: Although intravenous antibiotics have historically been the standard of care for bone and joint infections, clinical trial data have highlighted the safety and efficacy of oral antibiotics. Despite this, intravenous antibiotics are still commonly used, and evaluations of institutional guidelines advancing oral antibiotic use are limited. Methods: In April 2023, we implemented a new institutional guideline to preferentially treat patients with bone and joint infections with oral antibiotics. The postguideline cohort was compared with a historical preguideline cohort via retrospective chart review. The primary outcome was the proportion of patients discharged exclusively on oral antibiotics. Secondary outcomes included 90-day treatment failure, length of stay, and adverse effects. Results: One hundred eighty-six patients (53 preguideline and 133 postguideline) were included in the analysis. Patients in the postguideline cohort were more likely to be discharged exclusively on oral antibiotics (25% vs 70%; P < .01), with no difference in 90-day treatment failure (8% vs 9%; P = .75). Patients in the postguideline cohort had a shorter length of stay than preguideline (median, 8 vs 7 days; P = .04) and trended toward fewer peripherally inserted central catheter–related adverse events (6% vs 1%; P = .07). Conclusions: An institutional guideline was effective in increasing the proportion of patients with bone and joint infections discharged on oral antibiotics. We observed similar clinical outcomes after implementing the guidelines while reducing length of hospital stay.
- Open Access
- 13 March 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (4) , ofae143
Monthly Sulfadoxine-Pyrimethamine During Pregnancy Prevents Febrile Respiratory Illnesses: A Secondary Analysis of a Malaria Chemoprevention Trial in Uganda
Trials evaluating antimalarials for intermittent preventive treatment in pregnancy (IPTp) have shown that dihydroartemisinin-piperaquine (DP) is a more efficacious antimalarial than sulfadoxine-pyrimethamine (SP); however, SP is associated with higher birthweight, suggesting that SP demonstrates “nonmalarial” effects. Chemoprevention of nonmalarial febrile illnesses (NMFIs) was explored as a possible mechanism. In this secondary analysis, we leveraged data from 654 pregnant Ugandan women without HIV infection who participated in a randomized controlled trial comparing monthly IPTp-SP with IPTp-DP. Women were enrolled between 12 and 20 gestational weeks and followed through delivery. NMFIs were measured by active and passive surveillance and defined by the absence of malaria parasitemia. We quantified associations among IPTp regimens, incident NMFIs, antibiotic prescriptions, and birthweight. Mean “birthweight for gestational age” Z scores were 0.189 points (95% CI, .045–.333) higher in women randomized to IPTp-SP vs IPTp-DP. Women randomized to IPTp-SP had fewer incident NMFIs (incidence rate ratio, 0.74; 95% CI, .58–.95), mainly respiratory NMFIs (incidence rate ratio, 0.69; 95% CI, .48–1.00), vs IPTp-DP. Counterintuitively, respiratory NMFI incidence was positively correlated with birthweight in multigravidae. In total 75% of respiratory NMFIs were treated with antibiotics. Although overall antibiotic prescriptions were similar between arms, for each antibiotic prescribed, “birthweight for gestational age” Z scores increased by 0.038 points (95% CI, .001–.074). Monthly IPTp-SP was associated with reduced respiratory NMFI incidence, revealing a potential nonmalarial mechanism of SP and supporting current World Health Organization recommendations for IPTp-SP, even in areas with high-grade SP resistance. While maternal respiratory NMFIs are known risk factors of lower birthweight, most women in our study were presumptively treated with antibiotics, masking the potential benefit of SP on birthweight mediated through preventing respiratory NMFIs.
- 13 March 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (4) , ofae143
Open AccessMonthly Sulfadoxine-Pyrimethamine During Pregnancy Prevents Febrile Respiratory Illnesses: A Secondary Analysis of a Malaria Chemoprevention Trial in Uganda
Trials evaluating antimalarials for intermittent preventive treatment in pregnancy (IPTp) have shown that dihydroartemisinin-piperaquine (DP) is a more efficacious antimalarial than sulfadoxine-pyrimethamine (SP); however, SP is associated with higher birthweight, suggesting that SP demonstrates “nonmalarial” effects. Chemoprevention of nonmalarial febrile illnesses (NMFIs) was explored as a possible mechanism. In this secondary analysis, we leveraged data from 654 pregnant Ugandan women without HIV infection who participated in a randomized controlled trial comparing monthly IPTp-SP with IPTp-DP. Women were enrolled between 12 and 20 gestational weeks and followed through delivery. NMFIs were measured by active and passive surveillance and defined by the absence of malaria parasitemia. We quantified associations among IPTp regimens, incident NMFIs, antibiotic prescriptions, and birthweight. Mean “birthweight for gestational age” Z scores were 0.189 points (95% CI, .045–.333) higher in women randomized to IPTp-SP vs IPTp-DP. Women randomized to IPTp-SP had fewer incident NMFIs (incidence rate ratio, 0.74; 95% CI, .58–.95), mainly respiratory NMFIs (incidence rate ratio, 0.69; 95% CI, .48–1.00), vs IPTp-DP. Counterintuitively, respiratory NMFI incidence was positively correlated with birthweight in multigravidae. In total 75% of respiratory NMFIs were treated with antibiotics. Although overall antibiotic prescriptions were similar between arms, for each antibiotic prescribed, “birthweight for gestational age” Z scores increased by 0.038 points (95% CI, .001–.074). Monthly IPTp-SP was associated with reduced respiratory NMFI incidence, revealing a potential nonmalarial mechanism of SP and supporting current World Health Organization recommendations for IPTp-SP, even in areas with high-grade SP resistance. While maternal respiratory NMFIs are known risk factors of lower birthweight, most women in our study were presumptively treated with antibiotics, masking the potential benefit of SP on birthweight mediated through preventing respiratory NMFIs.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
338. ChatGPT Conveys Incorrect Information about the FDA’s Antibiotic Boxed Warnings
Chat Generative Pre-training Transformer (ChatGPT) is a popular artificial intelligence-based chatbot that rapidly provides responses to online inquiries. As a language-processing – rather than a scientific – tool, ChatGPT does not guarantee accuracy. The United States Food and Drug Administration (FDA) labels medications with significant risk of serious or life-threatening adverse effects with boxed warnings (BW). We sought to assess the accuracy of ChatGPT regarding FDA BW for antibiotics. (1) “Matching”: ChatGPT accurately reported both existence and content of BW or its absence; (2) “Inaccurate”: ChatGPT accurately reported a BW but erred on some aspects of the content; and (3) “Incorrect”: ChatGPT misidentified existence of BW, or listed incorrect adverse effects (AE) FDA Boxed Warnings for Commonly Used Antibiotics ChatGPT Responses about FDA Boxed Warnings Examples of Incorrect ChatGPT claims ChatGPT reported inaccurate and incorrect information about FDA BW for antibiotics. Clinicians should be aware of this new source of information for patients. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access338. ChatGPT Conveys Incorrect Information about the FDA’s Antibiotic Boxed Warnings
Chat Generative Pre-training Transformer (ChatGPT) is a popular artificial intelligence-based chatbot that rapidly provides responses to online inquiries. As a language-processing – rather than a scientific – tool, ChatGPT does not guarantee accuracy. The United States Food and Drug Administration (FDA) labels medications with significant risk of serious or life-threatening adverse effects with boxed warnings (BW). We sought to assess the accuracy of ChatGPT regarding FDA BW for antibiotics. (1) “Matching”: ChatGPT accurately reported both existence and content of BW or its absence; (2) “Inaccurate”: ChatGPT accurately reported a BW but erred on some aspects of the content; and (3) “Incorrect”: ChatGPT misidentified existence of BW, or listed incorrect adverse effects (AE) FDA Boxed Warnings for Commonly Used Antibiotics ChatGPT Responses about FDA Boxed Warnings Examples of Incorrect ChatGPT claims ChatGPT reported inaccurate and incorrect information about FDA BW for antibiotics. Clinicians should be aware of this new source of information for patients. All Authors: No reported disclosures
- Open Access
- 22 June 2023
- Published by Springer Nature in Research Square
A modified Michaelis-Menten equation estimates growth from birth to 3 years in healthy babies in the US
Background and Objectives: Standard pediatric growth curves cannot be used to impute missing height or weight measurements in individual children. The Michaelis-Menten equation, used for characterizing substrate-enzyme saturation curves, has been shown to model growth in many organisms including nonhuman vertebrates. We investigated this equation could be used to interpolate missing growth data in children in the first three years of life. Methods: We developed a modified Michaelis-Menten equation and compared expected to actual growth, first in a local birth cohort (N=97) then in a large, outpatient, pediatric sample (N=14,695). Results: The modified Michaelis-Menten equation showed excellent fit for both infant weight (median RMSE: boys: 0.22kg [IQR:0.19; 90%Conclusions: A modified Michaelis-Menten equation accurately describes growth in healthy babies aged 0-36 months, allowing interpolation of missing weight and height values in individual longitudinal measurement series. The growth pattern in healthy babies in resource-rich environments mirrors an enzymatic saturation curve.
- 22 June 2023
- Published by Springer Nature in Research Square
Open AccessA modified Michaelis-Menten equation estimates growth from birth to 3 years in healthy babies in the US
Background and Objectives: Standard pediatric growth curves cannot be used to impute missing height or weight measurements in individual children. The Michaelis-Menten equation, used for characterizing substrate-enzyme saturation curves, has been shown to model growth in many organisms including nonhuman vertebrates. We investigated this equation could be used to interpolate missing growth data in children in the first three years of life. Methods: We developed a modified Michaelis-Menten equation and compared expected to actual growth, first in a local birth cohort (N=97) then in a large, outpatient, pediatric sample (N=14,695). Results: The modified Michaelis-Menten equation showed excellent fit for both infant weight (median RMSE: boys: 0.22kg [IQR:0.19; 90%Conclusions: A modified Michaelis-Menten equation accurately describes growth in healthy babies aged 0-36 months, allowing interpolation of missing weight and height values in individual longitudinal measurement series. The growth pattern in healthy babies in resource-rich environments mirrors an enzymatic saturation curve.